-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hunan Fangsheng Pharmaceutical Co., Ltd. and its controlling subsidiary Xiangya Pharmaceutical Co., Ltd. signed the "Drug Production Technology Transfer Agreement" and decided to transfer the drug production technology of "Adefwe ester capsules" to Xiangya Pharmaceuticals for RMB0.About Adelfovir capsules
Adelfovir capsules are suitable for the treatment of adult chronic hepatitis B patients with evidence of replication of hepatitis B virus activity, accompanied by a persistent increase in serum amino transferase (ALT or AST) or liver histological activity lesions.
news that Fangsheng Pharmaceuticals decided to transfer the production technology of Adelfowe ester capsules to Xiangya Pharmaceuticals, after consensus between the two sides, the transaction is priced at 0 yuan, that is, free. This transfer is conducive to the company's concentrated resources to further enhance the market competitiveness of Adelphid ester dispersion tablets and tablets, at the same time, can improve the efficiency of asset use, effectively enrich Xiangya Pharmaceutical's product category, can expand its business scope.